Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 134Lung Neoplasms 50Adenocarcinoma of Lung 18Adenocarcinoma, Bronchiolo-Alveolar 10Brain Neoplasms 9NSCLC 8Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma 4Respiratory Tract Diseases 3Carcinoma 3Thoracic Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Recurrence 1Previous Treated Metastatic Non-small Cell Lung Cancer 1Pleural Effusion, Malignant 1Parathyroid Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1

Interventions

S 1 (combination) 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NSCLC With EGFR Mutation × Gefitinib × Thoracic × Clear all
NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Henan Cancer Hospital

Phase 2 Unknown
200 enrolled
Thoracic

Advanced NSCLC With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡